About: Comments on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al.(2020)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comments on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al.(2020) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comments on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al.(2020)
Creator	Chiappelli, Francesco
Source	Medline; PMC
abstract	covid:PMC7434959#abstract
has issue date	2020-05-31(xsd:dateTime)
bibo:doi	10.6026/97320630016432
bibo:pmid	32831526
has license	cc-by
schema:url	https://doi.org/10.6026/97320630016432
resource representing a document's title	Comments on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al.(2020)
has PubMed Central identifier	PMC7434959
has PubMed identifier	32831526
schema:publication	Bioinformation
resource representing a document's body	covid:PMC7434959#body_text
is schema:about of	named entity 'Structure-based design' named entity 'antiviral drug' named entity 'protease' named entity 'X-ray crystallography' named entity 'enzyme' named entity 'SARS-CoV2' named entity 'ng/mL' named entity 'SARS' named entity 'substrate-binding pocket' named entity 'SARS-CoV-2' named entity 'virus' named entity 'Mpro' named entity 'causative agent' named entity 'CoViD-19' named entity 'genome' named entity 'cysteine protease' named entity 'maximal concentration' named entity 'bioavailability' named entity 'SARS-CoV2' named entity '17.4' named entity 'non-structural proteins' named entity 'protease' named entity 'viral proteins' named entity 'ketoamide' named entity 'CoViD-19 pandemic' named entity 'highly conserved' named entity 'clearance rate' named entity 'aldehyde groups' named entity 'toxicity' named entity 'clinically relevant' named entity 'SARS-CoV2' named entity 'SARS-CoV2' named entity 'infection' named entity 'the development' named entity 'experimental study' named entity 'critical role' named entity 'Mpro' named entity 'X-ray structures' named entity 'Phase 1' named entity 'SARS-CoV' named entity 'lead compounds' named entity 'Mpro' named entity 'covalently bound' named entity 'virus' named entity 'unliganded' named entity 'CoViD-19' named entity 'open reading frames' named entity 'Mpro' named entity 'RNA genome' named entity 'nucleocapsid' named entity 'Mpro' named entity 'SARS-CoV2' named entity 'responsible for' named entity 'antivirals' named entity 'pharmacokinetic' named entity 'metabolic stability' named entity 'protease' named entity 'infection' named entity 'half-life' named entity 'Mpro' named entity 'nucleocapsid' named entity 'Mpro' named entity 'intraperitoneal' named entity 'viral genome' named entity '3C-like protease' named entity 'SARS-CoV2' named entity 'transcription' named entity 'PDB' named entity 'Mpro' named entity 'SARS-CoV-2' named entity 'ANTIVIRAL DRUG' named entity 'Structure-based design' named entity 'antiviral drug' named entity 'candidates' named entity 'Dai' named entity 'protease' named entity 'targeting' named entity 'SARS-COV-2' named entity 'COMMENTS' named entity 'MAIN' named entity 'STRUCTURE' named entity 'Comments'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software